NCT03315494View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

September 22, 2016

Primary Completion Date

December 21, 2016

Study Completion Date

December 21, 2016

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

SKI-O-703 capsule

SKI-O-703 200 mg capsule with no inactive excipients.

DRUG

Placebo capsule

Placebo 180 mg capsule filled with microcrystalline cellulose.

Trial Locations (1)

78744

PPD Development, LP, Austin

Sponsors

Lead Sponsor

Collaborators (1)

PPD Development, LP

All Listed Sponsors

collaborator

PPD Development, LP

INDUSTRY

lead

Oscotec Inc.

INDUSTRY